Akzo N.v.

Other

Akzo Nobel N.v.

Per Immune Holdings, Inc.

Richard P McCabe

Nicholas Pomato

Reinhard Bredehorst

Carl-Wilhelm Ernst Vogel

Chong-Ho Kim

Gregory Alan Hawkins

James Glessner, Jr

Martin V Haspel

Janet H Ransom

Meredith Ware

Gregory A Hawkins

A method for making a low embodied energy cementitious mixture by blending a variety of post-consumer wastes, post-industrial wastes, as well as renewable, organic and recyclable materials with Portland cement or a material having similar cementitious properties. The primary materials are recycled concrete, coal-fired fly ash waste, silica fume, post-industrial waste, organic or inorganic waste fibers. Glass, brick, ceramics, ground tires and other waste products, as well as virgin aggregate can also be included in the low embodied energy cementitious mixture.

Low embodied energy concrete mixture

A method for making a low embodied energy cementitious mixture by blending a variety of post-consumer wastes, post-industrial wastes, as well as renewable, organic and recyclable materials with Portland cement or a material having similar cementitious properties. The primary materials are recycled concrete, coal-fired fly ash waste, silica fume, post-industrial waste, organic or inorganic waste fibers. Glass, brick, ceramics, ground tires and other waste products can also be included.

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

In vivo binding pair pretargeting

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.

A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.

Site specific in vivo activation of therapeutic drugs

Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000, with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between 4.8 and 5.5 or between 7.5 and 8.3, which has the ability to regulate tumor cell physiology and growth without affecting the growth of normal cells. Methods for stimulating its production by monouclear cells, methods for its isolation and purification, and methods for its therapeutic uses are also disclosed.

Growing community of inventors

West Chester, PA, United States of America

Richard P McCabe